Inclusion Criteria:

- Cytologically or histologically confirmed adenocarcinoma of the exocrine pancreas

- Disease non-resectable and locally advanced or metastatic

- Measurable disease or evaluable disease i.e. tumor marker CA19-9 at baseline ≥ 1.5 x
upper limit of normal (ULN)

- Age >18 years

- Karnofsky performance status ≥ 60%

- Life expectancy of at least 3 months

- Written informed consent

- Willing and able to comply with the protocol for the duration of the study

Exclusion Criteria:

- Prior chemotherapy for pancreatic cancer

- Prior adjuvant radio- or radiochemotherapy for pancreatic cancer within 12 months of
inclusion

- Known CNS metastases at the time of enrollment

- Neutrophil count ≤ 1.5 x109/l, platelet count ≤100 x109/l, hemoglobin ≤ 10g/dl

- Serum creatinine > 1.25 x ULN

- ASAT, ALAT and alkaline phosphatase > 2.5 ULN or > 5 ULN in the presence of liver
metastasis, Bilirubin > 1.5 ULN (after treatment of obstructive jaundice eg. stent)

- Pregnant or breast feeding women (women of childbearing potential must have a
negative pregnancy test at baseline)

- Men and women of reproductive potential who are not using an effective method of
contraception

- Clinically significant cardiac disease (NYHA III-IV) or myocardial infarction within
the last 12 months

- Neurological disease with dys-/paraesthesias > grade 1 according to NCI CTC

- Any serious concomitant disorder incompatible with the trial (in the judgement of the
investigator)

- Psychiatric disability thought to be clinically significant in the opinion of the
investigator precluding informed consent or interfering with compliance